#MathOnco Issue 135: bayesian radiotherapy, non-genetic resistance, stochastic PK/PD models, persistence, and drug-induced resistance.
This week in
Math Oncology
Oct. 15, 2020 ~ Issue 135
From the editor
Dear readers,
Today's issue contains articles on the topics of bayesian radiotherapy, non-genetic resistance, stochastic PK/PD models, persistence, and drug-induced resistance.
I've also included a new box for the growing list of relevant journal special issues where you might want to submit your math oncology preprints.
Enjoy,
-Jeffrey West
#MathOnco Publications
Evolutionary Dynamics in Vascularised Tumours under Chemotherapy: Mathematical Modelling, Asymptotic Analysis and Numerical Simulations
Authors: Chiara Villa, Mark A. J. Chaplain & Tommaso Lorenzi
Bayesian Information-Theoretic Calibration of Radiotherapy Sensitivity Parameters for Informing Effective Scanning Protocols in Cancer
Authors: Heyrim Cho, Allison L. Lewis, Kathleen M. Storey
Beyond Deterministic Models in Drug Discovery and Development
Authors: Itziar Irurzun-Arana, Christopher Rackauckas, Thomas O.McDonald, Iñaki F. Trocóniz
Non-genetic mechanisms of therapeutic resistance in cancer
Authors: Jean-Christophe Marine, Sarah-Jane Dawson, Mark A. Dawson
#MathOnco Preprints
An experimental-mathematical approach to predict tumor cell growth as a function of glucose availability in breast cancer cell lines
Authors: Jianchen Yang, Jack Virostko, David A. Hormuth, Junyan Liu, Amy Brock, Jeanne Kowalski, Thomas Yankeelov
Evolutionary dynamics at the tumor edge reveals metabolic imaging biomarkers
Authors: Juan Jiménez-Sánchez, Jesús J. Bosque, Germán A. Jiménez-Londoño, David Molina-García, View ORCID ProfileÁlvaro Martínez-Rubio, Julián Pérez-Beteta, Carmen Ortega-Sabater, Antonio F. Honguero-Martínez, Ana M. García-Vicente, Gabriel F. Calvo, Víctor M. Pérez-García
Drug-induced resistance evolution necessitates less aggressive treatment
Authors: Teemu Kuosmanen, Johannes Cairns, Robert Noble, Niko Beerenwinkel, Tommi Mononen, Ville Mustonen
Synonymous mutations reveal genome-wide driver mutation rates in healthy tissues
Authors: Gladys Poon, Caroline J. Watson, Daniel S. Fisher, Jamie R. Blundell
Persistence as an optimal hedging strategy
Authors: Alexander P Browning, Jesse A Sharp, Tarunendu Mapder, Christopher M Baker, Kevin Burrage, Matthew J Simpson
The impact of preprint servers in the formation of novel ideas
Authors: Swarup Satish, Zonghai Yao, Andrew Drozdov, Boris Veytsman
Stochastic stem cell models with mutation: A comparison of asymmetric and symmetric divisions
Authors: Zhijie Wu, Yuman Wang, Kun Wang, Da Zhou
Immune surveillance and immunoediting in microsatellite-unstable cancers
Nature Cancer | Cancer Community
Matthias Kloor: "Importantly, studying cancer evolution is not only a fascinating exercise in basic science, it also has meaningful clinical implications. Individuals affected by Lynch syndrome, the most common hereditary cancer syndrome caused by germline variants in DNA mismatch repair (MMR) genes1, have a more than 50% life-time risk of developing MMR-deficient cancer. Therefore, there is a big medical need for novel approaches for effective tumor prevention in Lynch syndrome. For developing such prevention strategies, understanding the evolution of MMR-deficient cancers over time is essential."
#MathOnco Virtual Seminars
Moffitt's Integrated Mathematical Oncology Dept. Series
Mathematical Oncology Series
1. Dr. Arturo Aarujo
"Modelling cell division to understand clinical outcomes: Investigations in Oesophageal, Colon and Prostate to Bone Metastasis"
Oct 15, 2020 12:00pm US Eastern
2. Dr. Hermann Frieboes
"Modulation of Immune Response to Cancer via Nanotherapy: An Integrated Experimental/Mathematical Modeling Perspective"
Dec 10, 2020 12:00pm US Eastern
#MathOnco - Featured Book
Rebel Cell: Cancer, Evolution, and the New Science of Life's Oldest Betrayal
Kat Arney: "Cancer exists in nearly every animal and has afflicted humans as long as our species has walked the earth. In Rebel Cell: Cancer, Evolution, and the New Science of Life's Oldest Betrayal, Kat Arney reveals the secrets of our most formidable medical enemy, most notably the fact that it isn’t so much a foreign invader as a double agent: cancer is hardwired into the fundamental processes of life. New evidence shows that this disease is the result of the same evolutionary changes that allowed us to thrive. Evolution helped us outsmart our environment, and it helps cancer outsmart its environment as well—alas, that environment is us."
Special Issues
"Mathematical Models of Cellular Immunotherapies in Cancer"
Guest Editors: V. Pérez-García, L. de Pillis, P. Altrock, R. RockneLatest Developments in Mathematical Oncology and Cancer Systems Biology
Guest Editors: M. Kumar Jolly, H. EnderlingFrom Ecology to Cancer Biology and Back Again
Guest Editors: Fred Adler, Sarah Amend, Chris WhelanFrontiers in quantitative cancer modeling
Guest Editors: Mohit Kumar Jolly, Heiko Enderling
Jobs
Research Fellow in Systems Biology Cancer Research (Simon Mitchell)
Principal Scientist – Oncology PK/PD Modelling (Boehringer Ingelheim)
Postdoctoral Research Position in Computational Immunology (Sylvain Cussat-Blanc)
Postdoc Position - TKI treatments in lung cancer (David Basanta)
Systems Biology Modeler Positions in Biopharma Consulting Company (Helen Moore)
Computational Approaches to Breast Cancer Evolution - Postdoc (Marc Ryser)
Math/statistical models of stem cell lineage dynamics and cancer genomics - Postdoc (Adam MacLean)
Postdoctoral Research Position in Computational Oncology (Tom Yankeelov)
Do you see something we missed? Reply to this email to send us an idea for next week's issue.
The #MathOnco newsletter is maintained by Jeffrey West.
If you were forwarded this email, subscribe for free here to get it delivered every week.